Literature DB >> 19569734

Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.

H He1, K A Lyons, X Shen, Z Yao, K Bleasby, G Chan, M Hafey, X Li, S Xu, G M Salituro, L H Cohen, W Tang.   

Abstract

1. Drug concentrations in cerebrospinal fluid have been assumed to be a natural surrogate for total drug exposures in the central nervous system. The present communication reports a data set from a study of 30 compounds in mice. An attempt was made to correlate cerebrospinal fluid and unbound plasma drug concentrations via incorporation of in vitro P-glycoprotein (Pgp)-mediated transport data. 2. Pgp-deficient (Pgp -/-) and wild-type mice were dosed with compounds of interest by oral gavage (orally) at 5 mg kg(-1). Plasma and cerebrospinal fluid samples were collected at 1 h post-dosing, and analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for drug concentrations. Mouse and human Pgp-mediated transport were evaluated in vitro by a bi-directional (B to A and A to B) transport assay using LLC-PK1 cells expressing mouse (mdr1a) and human (MDR1) forms of Pgp, respectively. 3. Compounds with B to A/A to B transport ratios < 2 were defined as non-substrates of Pgp, whereas those exhibiting B to A/A to B transport ratios > or =2 were considered Pgp substrates. Plasma protein binding was also determined in vitro via equilibrium dialysis. Of the 30 compounds, 13 were identified to be mouse Pgp substrates, all of which were also human Pgp substrates, demonstrating a good agreement between mouse and human data. 4. In Pgp wild-type mice, the unbound plasma and cerebrospinal fluid concentrations of the non-Pgp substrates correlated well, with a regression slope of approximately 1.0. A similar relationship existed for Pgp substrates in Pgp -/- mice. On the other hand, an improved correlation of cerebrospinal fluid and systemic exposures of the Pgp substrates in Pgp wild-type mice was observed when the unbound plasma concentrations were normalized to the corresponding B to A/A to B transport ratios. 5. These results reinforce the premise that a combined use of unbound plasma drug concentrations and in vitro Pgp transport data may be of value for the estimation of central nervous system exposures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19569734     DOI: 10.1080/00498250903015402

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.

Authors:  William T McElroy; Zheng Tan; Ginny Ho; Sunil Paliwal; Guoqing Li; W Michael Seganish; Deen Tulshian; James Tata; Thierry O Fischmann; Christopher Sondey; Hong Bian; Loretta Bober; James Jackson; Charles G Garlisi; Kristine Devito; James Fossetta; Daniel Lundell; Xiaoda Niu
Journal:  ACS Med Chem Lett       Date:  2015-05-12       Impact factor: 4.345

2.  Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

Authors:  Liangqin Guo; Dann L Parker; Yi Zang; Ramzi F Sweis; Weiguo Liu; Edward C Sherer; Nicole Buist; Jenna Terebetski; Terri Kelly; Randal Bugianesi; Birgit T Priest; Karen H Dingley; Xiaofang Li; Stan Mitelman; Gino Salituro; Maria E Trujillo; Michele Pachanski; Melissa Kirkland; Mary Ann Powles; George J Eiermann; Yue Feng; Jin Shang; Andrew D Howard; Feroze Ujjainwalla; Christopher J Sinz; John S Debenham; Scott D Edmondson; Ravi P Nargund; William K Hagmann; Derun Li
Journal:  ACS Med Chem Lett       Date:  2016-10-12       Impact factor: 4.345

3.  Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development.

Authors:  Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

4.  Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.

Authors:  Shrenik K Shah; Shuwen He; Liangqin Guo; Quang Truong; Hongbo Qi; Wu Du; Zhong Lai; Jian Liu; Tianying Jian; Qingmei Hong; Peter Dobbelaar; Zhixiong Ye; Edward Sherer; Zhe Feng; Yang Yu; Frederick Wong; Koppara Samuel; Maria Madiera; Bindhu V Karanam; Vijay B Reddy; Stan Mitelman; Sharon X Tong; Gary G Chicchi; Kwei-Lan Tsao; Dorina Trusca; Yue Feng; Margaret Wu; Qing Shao; Maria E Trujillo; George J Eiermann; Cai Li; Michele Pachanski; Guillermo Fernandez; Donald Nelson; Patricia Bunting; Pierre Morissette; Sylvia Volksdorf; Janet Kerr; Bei B Zhang; Andrew D Howard; Yun-Ping Zhou; Alexander Pasternak; Ravi P Nargund; William K Hagmann
Journal:  ACS Med Chem Lett       Date:  2015-03-18       Impact factor: 4.345

5.  Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.

Authors:  Rebecca Nofsinger; Sophie-Dorothee Clas; Rosa I Sanchez; Abbas Walji; Kimberly Manser; Becky Nissley; Jaume Balsells; Amrithraj Nair; Qun Dang; David Jonathan Bennett; Michael Hafey; Junying Wang; John Higgins; Allen Templeton; Paul Coleman; Jay Grobler; Ronald Smith; Yunhui Wu
Journal:  Pharmaceuticals (Basel)       Date:  2014-02-24

6.  Construction of P-glycoprotein incorporated tethered lipid bilayer membranes.

Authors:  Fatih Inci; Umit Celik; Basak Turken; Hakan Özgür Özer; Fatma Nese Kok
Journal:  Biochem Biophys Rep       Date:  2015-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.